TUCSON, Ariz., March 3, 2015 /PRNewswire/ -- The eleventh
annual Tucson Symposium will be held March
17-18, where more than 450 of the world's top research
scientists, academics, oncologists and pathologists will gather to
debate new findings, discuss evolving theories and learn about new
outcomes in patient treatments that may significantly affect the
practice of medicine.
Each year Ventana Medical Systems, Inc. (Ventana), a member of
the Roche Group, sponsors the Tucson Symposium at the Hilton El
Conquistador in Tucson, Arizona to
provide a forum for thought leaders to share new scientific
achievements in cancer research and medical practice. Dr.
Dan Von Hoff from the Translational
Genomics Research Institute will deliver the opening keynote
address.
"The Tucson Symposium continues to draw the best scientific
minds in the industry," says Ventana Founder and Chief
Scientific Advisor Dr. Thomas
Grogan. "We look forward to again creating a pioneering
environment where scientific collaborators can discover new
technologies and advancements in pathology and oncology that can
improve patients' lives."
At this year's event, participants will explore the latest
advancements in breast cancer biology and biomarkers, personalized
healthcare, cancer genomics, immunotherapy and cancer heterogeneity
and evolution – technologies that are transforming current
healthcare practices.
"Year after year, Ventana has included its collaborators in
scientific discussions. The forum is an excellent opportunity to
exchange knowledge, experience and new ideas on an
interdisciplinary level. The meeting has continued to strengthen
the company's focus on innovation and enables an unparalleled
intimate exchange among practitioners, researchers and industry,"
said Dr. Manfred Dietel, Medical
Director of the Institute of Pathology, University Hospital
Charite, Berlin, Germany.
For more information about the Symposium, please visit
www.tucsonsymposium.com.
About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX:
RHHBY), a member of the Roche Group, innovates and manufactures
instruments and reagents that automate tissue processing and slide
staining for cancer diagnostics. VENTANA products are used in
clinical histology and drug development research laboratories
worldwide. The company's intuitive, integrated staining, workflow
management platforms, and digital pathology solutions optimize
laboratory efficiencies to help reduce errors, support diagnosis
and enable informed treatment decisions by anatomic pathology
professionals. Together with Roche, VMSI is driving Personalized
Healthcare through accelerated drug discovery and the development
of companion diagnostics to identify the patients most likely to
respond favorably to specific therapies.
Visit www.ventana.com to learn more.
© 2015 Ventana Medical Systems, Inc.
VENTANA and the VENTANA logo are trademarks of Roche.
All other trademarks are the property of their respective
owners.
VMSI Media Relations
Jacqueline Bucher
Head of Corporate Communications
Phone: 520-877-7288
e-mail: Jacquie Bucher
Photo - http://photos.prnewswire.com/prnh/20150302/178974
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global-scientific-collaborators-to-explore-latest-pathology-and-oncology-advancements-at-tucson-symposium-300044129.html
SOURCE Ventana Medical Systems, Inc.